NEW YORK, Nov. 29, 2016 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today the appointment of Gregory Bergonio, M.S.H.S., to the position of Director of Clinical Operations. Mr. Bergonio’s initial responsibility will be focusing on the advancement of the Actimab-A Phase 2 clinical trial as well as earlier stage clinical programs that the company plans to undertake.
“We are very excited to welcome Greg to the clinical development team at Actinium,” said Sandesh Seth, Actinium’s Executive Chairman. “Greg’s joining comes at an ideal time given our increased development efforts as a result of the Actimab-A Phase 2 trial and Iomab-B pivotal Phase 3 SIERRA trial. Greg’s direct experience in AML and significant knowledge of clinical trial management will have an immediate impact on our capabilities that we expect will add efficiency and scale to our current and planned clinical development efforts.”
Most recently, Mr. Bergonio worked at Novartis as an expert clinical manager in their oncology global development unit with a focus on acute myeloid leukemia (AML). At Novartis, Greg managed a wide array of clinical development activities focused on driving effective operations at clinical trials sites on an international basis. In addition, he coordinated interdisciplinary efforts focused on inspection preparation activities associated with the new drug application (NDA) submissions at the site and sponsor level. Prior to Novartis, Greg worked at a number of large multi-national pharmaceutical companies and CROs including Bausch & Lomb, OSI, Forest Laboratories, Inc. and Kern McNeill International where he gained experience in the therapeutic areas of oncology, cardiology, CNS and ophthalmology. Greg has a Master of Science Degree in Health Sciences with a focus on Clinical Research Administration from George Washington University and a Bachelor of Science Degree in Nursing from Fairleigh Dickinson University.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options. Actinium's proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. The Company's lead product candidate Iomab-B is designed to be used, upon approval, in preparing patients for a hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. A bone marrow transplant is often the only potential cure for patients with blood-borne cancers but the current standard preparation for a transplant requires high-dose chemotherapy and/or total body irradiation that result in significant toxicities. Actinium believes Iomab-B will enable a faster and less toxic preparation of patients seeking a bone marrow transplant, leading to increased transplant success and survival rates. The Company is currently conducting a single pivotal 150-patient, multicenter Phase 3 clinical study of Iomab-B in patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The Company's second product candidate, Actimab-A, is currently in a multicenter open-label, 53-patient Phase 2 trial for patients newly diagnosed with AML age 60 and over. Actimab-A is being developed to induce remissions in elderly patients with AML who lack effective treatment options and often cannot tolerate the toxicities of standard frontline therapies. Actinium is also utilizing its alpha-particle immunotherapy (APIT) technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors.
Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
CONTACT: Contact: Actinium Pharmaceuticals, Inc. Steve O'Loughlin Vice President, Finance and Corporate Development firstname.lastname@example.org